SCHEMBL9944289

SCHEMBL9944289

CC(C)Oc1cc(C(=O)Nc2ccc(C=O)c(F)c2)cc(Cl)c1OC(C)C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.46
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
RORC P51449 1/20 0.44
NPC1 O15118 6/20 0.43
RAB9A P51151 6/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
MAPT P10636 6/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944352 0.88 PLAU (0.44) PLAUKCNQ3KCNQ2RORCNPC1
SCHEMBL9944290 0.85 TP53 (0.50) KCNQ3KCNQ2SMN1; SMN2MAPTLMNA
SCHEMBL9944230 0.85 RORC (0.48) PLAUKCNQ3KCNQ2RORCNPC1
SCHEMBL1458495 0.84 PLAU (0.47) PLAUKCNQ3KCNQ2RORCNPC1
SCHEMBL9944353 0.82 TAS1R3 (0.50) PLAURORCNPC1RAB9ASMN1; SMN2
SCHEMBL9944283 0.81 PLAU (0.47) PLAURORCNPC1RAB9ASMN1; SMN2
SCHEMBL9944306 0.80 TAS1R3 (0.47) PLAUNPC1RAB9ASMN1; SMN2TAS1R3
SCHEMBL9944331 0.80 RAB9A (0.49) PLAURORCNPC1RAB9ASMN1; SMN2
SCHEMBL9944288 0.80 RAB9A (0.49) PLAURORCNPC1RAB9ASMN1; SMN2
SCHEMBL9944304 0.80 MAPT (0.50) PLAUNPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG PLAU 4014/4885KCNQ3 4487/4885KCNQ2 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.